Randomized trial · people
Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesity
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For obesity caused by hypothalamic damage, this year-long placebo-controlled trial adds evidence that setmelanotide lowered BMI and hunger, with more side effects, including serious ones, than placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 120
- Published
- 2026
- Journal
- N Engl J Med
What they tested
The team tested whether daily setmelanotide lowers BMI and hunger more than placebo in people whose obesity followed a hypothalamic tumor, lesion or injury.
How the study was done
A phase 3, randomized, placebo-controlled trial in 120 people aged 4 to 66 with acquired hypothalamic obesity: 81 got setmelanotide and 39 got placebo (a dummy shot), given once daily under the skin. Treatment ran for 52 weeks after a dose-escalation period, with trial doses of 1.5 to 3.0 mg.

Model. Individual results vary.
What they found
BMI (body-mass index, weight relative to height) changed by -16.5% on setmelanotide and by 3.3% on placebo at 52 weeks (P<0.001). In participants aged 12 and older, the weekly average of peak daily hunger, scored 0 to 10, fell by 2.73 points on setmelanotide and by 1.45 points on placebo (P = 0.009). Adverse events occurred in 100% of the setmelanotide group and 90% of the placebo group, and serious adverse events in 28% and 8%. The most common side effects on setmelanotide were skin darkening (hyperpigmentation), nausea, vomiting and headache.
What it doesn’t show
The trial lasted 52 weeks and included only people with obesity after hypothalamic damage, so it does not show longer-term effects or results in other kinds of obesity. Hunger was measured only in those aged 12 and older, and the trial was funded by Rhythm Pharmaceuticals.
The paper
Miller et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weightClinical trial · people · 2020
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.